Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiaceuticsDIUXF 80 3-Year EBITDA Growth Rate is 19.30% as of Dec. 2025, which is 245% above its 10-year median of 5.60. GuruFocus rates DIUXF with a GF Score™ of 80/100 and a GF Value™ of $2.06 (Fairly Valued). The stock has 1 warning sign investors should review. Among 525 Healthcare Providers & Services companies, Diaceutics ranks better than 65.33% on this metric.
During the past 12 months, Diaceutics's average EBITDA Per Share Growth Rate was 121.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 19.30% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 67.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Diaceutics was 143.80% per year. The lowest was -46.40% per year. And the median was 5.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Diaceutics 3-Year EBITDA Growth Rate Related Terms
DIUXF vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Diaceutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diaceutics 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diaceutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Diaceutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 19.30% mean?
Diaceutics (DIUXF) has a 3-Year EBITDA Growth Rate of 19.30% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Diaceutics and its competitors. This is 245% above median its historical median of 5.60. According to the industry distribution chart, Diaceutics ranks #182 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 34.7%.
Is Diaceutics' 3-Year EBITDA Growth Rate too high?
Diaceutics' current 3-Year EBITDA Growth Rate of 19.30% is 245% above median its 10-year median of 5.60. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.20. Diaceutics' value of 19.30% is 89.2% above this industry median. Based on the distribution chart, Diaceutics ranks #182 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Diaceutics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diaceutics' 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diaceutics ranks #182 out of 525 companies for 3-Year EBITDA Growth Rate. This puts Diaceutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.20. Diaceutics' value of 19.30% is 89.2% above this benchmark. While the company's 10-year median is 5.60 vs. the industry median of 10.20, Diaceutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.20, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diaceutics's current 3-Year EBITDA Growth Rate of 19.30% is 89.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Diaceutics and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diaceutics's current 3-Year EBITDA Growth Rate is 19.30%, which is 245% above median its own 10-year median of 5.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diaceutics stock overvalued right now?
Based on GuruFocus' analysis, Diaceutics (DIUXF) is currently considered Fairly Valued. The stock's GF Value™ is $2.06, compared to a current price of $2.00 — trading 2.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 19.30%, which is 245% above median its 10-year median of 5.60 and 89.2% above the Healthcare Providers & Services industry median of 10.20. Diaceutics' overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Diaceutics (DIUXF), the current 3-Year EBITDA Growth Rate is 19.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diaceutics (DIUXF) Overvalued in 2026?
Based on GuruFocus' analysis, Diaceutics stock appears to be undervalued.
The current stock price of $2.00 is trading 2.9% below its estimated GF Value™ of $2.06.
GuruFocus considers Diaceutics to be Fairly Valued.
Key valuation signals for DIUXF:
3-Year EBITDA Growth Rate: 19.30% (245% above median its 10-year median of 5.60)
GF Value™: $2.06 vs. price of $2.00 (2.9% below fair value)
Industry Position: 89.2% above the Healthcare Providers & Services median (#182 of 525)
No single metric tells the full story. See the DIUXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diaceutics PLC is a data analytics and implementation services company that services the pharmaceutical industry. It provides integrated commercialization solutions that help biopharma companies maximize patient access, accelerate uptake, and improve the lifetime value of their therapies. The group's services span the full commercial lifecycle, from pre-launch ideas through to mature brand optimization, delivered through an integrated combination of data, technology, and expertise. Its DXRX Data Solutions include DXRX Signal, DXRX Physician Segmentation, DXRX Lab Segmentation, and DXRX Disease Testing Rate Tracker. Geographical market by customer location in the UK, North America, Europe, Asia, and the rest of the world.
80GF Score
Get the complete analysis for DIUXF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DIUXF has been successfully added to your 
